Bubendorf, Switzerland, Thursday, December 8, 2022 – CIS Pharma has successfully tested its linker technology. The technology creates immuno-conjugates with higher uniformity and stability compared to immuno-conjugates based on commonly used linkers. Quantitative functionalization of CIS Pharma’s monoclonal antibodies – applying site-directed conjugation – results in an ADC with high homogeneity and a DAR at nearly maximal value. A stability study in human plasma showed superior results for the ADC compared to a conjugate comprising a conventional maleinimide-based linker technology. No signs of degradation or loss of DAR over time were observed with CIS Pharma’s linker technology, whereas the control loses most of its payload within 7 days at 37°C. Michael Hackebeil, Expert Polymer Chemistry, says: «In a consecutive study, our ADC also demonstrated excellent tolerability. The results are no surprise in the light of the high stability and homogeneity of the immuno-conjugates. Based on our polymer carrier technology and our linker technology we design immuno-conjugates with a DAR up to 16.»
About CIS Pharma antibody-drug conjugates, ADCs, and antibody radionuclide conjugates, ARCs
ADCs, antibody-drug conjugates, are a class of highly potent drugs for the treatment of cancer. Conventional ADCs are composed of a chemotherapeutic drug that is conjugated directly to an antibody targeting cancer cells. CIS Pharma has developed a polymer-drug-carrier, PDC, that is loaded with anticancer moieties and consequently linked to the antibody. The PDC platform allows for customization and optimization of ADCs for a given target and indication.
ARCs, antibody-radionuclide conjugates, are a form of radiotherapy, where a radionuclide molecule is linked to an antibody. CIS Pharma has developed a radionuclide-specific PDC that is optimized to conjugate radionuclides to an antibody. Radionuclides, such as Lutetium-177 or Iodine-131 are radioactive isotopes that emit radiation that kill cancer cells. Other radionuclides such as Indium-111 or Zirconium-89 are used for imaging and localization of cancer cells and to monitor the progress of cancer treatment.
Theranostics is a concept that refers to the integration of imaging and therapy in a single system, allowing therapy and follow-up of the treatment. CIS Pharma PDC’s are designed to conjugate both imaging and therapeutic compounds in a single system to simultaneously treat and monitor cancer. Alternatively, the identical antibody-polymer-drug-carrier-system is loaded in a first step with imaging radio-isotopes to then load in a second run therapeutic radio-isotopes to treat cancer.
About CIS Pharma AG
CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website www.cis-pharma.com.